What is Oppenheimer's price target for AMED?

Oppenheimer's latest stated price target for Amedisys Inc (AMED) is $200, from its action on Feb 25, 2022.

What is Oppenheimer's rating on AMED?

Oppenheimer rates AMED Outperform, a bullish rating, as of Feb 25, 2022.

When did Oppenheimer last change its view on AMED?

On Feb 25, 2022, Oppenheimer cuts its price target to $200 from $225, keeps Outperform.

Oppenheimer AMED price target and rating history

Oppenheimer rates Amedisys Inc (AMED) Outperform with a $200 price target, as of its latest action on Feb 25, 2022. It has published 3 rating actions on AMED since August 2021, including 0 upgrades and 0 downgrades.

Current rating: Outperform
Price target: $200
Median target, all firms: Too few
Actions on AMED: 3

Oppenheimer price target on AMED

Oppenheimer price target on AMED, each point a stated target, August 2021 to February 2022.

Every Oppenheimer rating on AMED

Feb 25, 2022
ReiterateOppenheimer cuts its price target to $200 from $225, keeps Outperform
Nov 3, 2021
ReiterateOppenheimer cuts its price target to $225 from $265, keeps Outperform
Aug 6, 2021
ReiterateOppenheimer cuts its price target to $265 from $325, keeps Outperform

Questions about Oppenheimer and AMED

What is Oppenheimer's price target for AMED?: Oppenheimer's latest stated price target for Amedisys Inc (AMED) is $200, from its action on Feb 25, 2022.
What is Oppenheimer's rating on AMED?: Oppenheimer rates AMED Outperform, a bullish rating, as of Feb 25, 2022.
When did Oppenheimer last change its view on AMED?: On Feb 25, 2022, Oppenheimer cuts its price target to $200 from $225, keeps Outperform.

More AMED rating histories

All Oppenheimer ratings AMED news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.